Krajina: Izrael
Jazyk: angličtina
Zdroj: Ministry of Health
BOSENTAN
J-C HEALTH CARE LTD
C02KX01
FILM COATED TABLETS
BOSENTAN 125 MG
PER OS
Required
ACTELION PHARMACEUTICALS LTD., SWITZERLAND
BOSENTAN
BOSENTAN
Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV.Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
2012-05-31
1 Tracleer 62.5 mg and Tracleer 125 mg_PI_ 8-2021 TRACLEER ® PRESCRIBING INFORMATION 1. NAME OF THE MEDICINAL PRODUCT Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ Tracleer 62.5 mg Each film-coated tablet contains 62.5 mg bosentan (as monohydrate). Tracleer 125 mg Each film-coated tablet contains 125 mg bosentan (as monohydrate). Excipient with known effect This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’ . For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablets): Orange-white, round, biconvex, film-coated tablets, embossed with “62,5” on one side. Orange-white, oval, biconvex, film-coated tablets, embossed with “125” on one side. A Patient Alert Card providing important safety information that patients need to be aware of before and during treatment with Tracleer is included in the pack. • WARNING: EMBRYO-FETAL TOXICITY Do not administer Tracleer to a pregnant female because it may cause fetal harm [see Contraindications (4.3) and Fertility, pregnancy and lactation (4.6)]. Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after stopping treatment by using acceptable methods of contraception [see Fertility, pregnancy and lactation (4.6)]. The marketing of Tracleer is subject to a Risk Evaluation and Mitigation Strategy (REMS) Program. Each patient should receive a Patient alert card, emphasizing the risks of embryo fetal toxicity. 2 Tracleer 62.5 mg and Tracleer 125 mg_PI_ 8-2021 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV. Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATI Prečítajte si celý dokument